Cas No.: | 13209-41-1 |
Chemical Name: | Vamorolone |
Synonyms: | Pregna-1,4,9(11)-triene-3,20-dione,17,21-dihydroxy-16-methyl-, (16a)-;16α-Methyl-9,11-dehydro Prednisolone;17,21-dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione;16α-Methyl-9,11-dehy;(8S,10S,13S,14S,16R,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one;Dexamethasone impurity E;(16α)-17,21-Dihydroxy-16-Methylpregna-1,4,9(11)-triene-3,20-dione;17.alpha.,21-Dihydroxy-16.alpha.-methylpregna-1,4,9(11)-triene-3,20-dione;Vamorolone |
SMILES: | OCC([C@]1(C(C)CC2C3CCC4=CC(C=CC4(C)C3=CCC12C)=O)O)=O |
Formula: | C22H28O4 |
M.Wt: | 356.45532 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Vamorolone (VBP-15) is a dissociative steroidal compound, reduces NF-κB-mediated cytokine expression in vitro, alsp reduecs glucocorticoid-mediated side-effects when compared to dexamethasone in vivo; reduces NF-κB pathway inflammatory cytokines in mouse primary DIPG cells, shows efficacy in inducing an anti-inflammatory response in animal models of asthma, multiple sclerosis, inflammatory bowel disease, and muscular dystrophies, and has shown fewer side effects; increases physical activity of tumor bearing mice. |